Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

Completed · Phase 2

Conditions studied: Gastroesophageal Reflux Disease

In brief

The primary objective of this study is to collect safety information on rabeprazole 10 mg and 20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16 years. The secondary objectives are to assess the efficacy of rabeprazole on the improvement of the symptoms of GERD and to explore the relationship of symptom relief to dose received, based on symptom frequency and severity, antacid use, and quality of life (QOL) measures.

Key facts

Study ID: NCT00132496
Run by: Eisai Inc.
People needed: 111
Starts: 2005-08-01
Expected to finish: 2006-07-01
Last updated by the study team: 2009-12-03

Who can join

Age: 12 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Males and females aged 12 to 16 years with a clinical diagnosis of symptomatic GERD or suspected or endoscopically proven GERD.
Patients who have ever been treated with, or are currently receiving proton pump inhibitors (PPIs),histamine receptor (H2) blockers, or antacids are eligible (as long as they can go off PPIs and H2 blockers for three days prior to dosing, except for cimetidine, which must be discontinued for at least seven days prior to dosing; exclusion criteria 5 and 6). Also, patients should be able to go off PPI therapy for two weeks at the end active drug treatment.
Children with stable asthma/reactive airways disease on stable treatment regimens are eligible.
Children on stable doses of allergy, antiepileptic, antidepressant, and attention deficit disorder medicines are eligible.
Patients must be able and willing to swallow the test drug tablet intact. The ability of the child to swallow an intact tablet must be confirmed by the site at Screening.
The patient is willing and able to give assent to participate.
The patient's parent or guardian gives written informed consent.
Post-pubertal females will be required to be abstinent during the course of the study.
Clinically insignificant laboratory findings.

You may not qualify if…

Evidence of significant hepatic, renal, respiratory, endocrine, immune, infectious, hematologic, neurologic, psychiatric, or cardiovascular system abnormalities that would interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study.
History of primary esophageal motility disorders or systemic condition affecting the esophagus (eg, scleroderma, esophageal infections).
History of eosinophilic esophagitis, persistent milk protein allergy, or allergic gastroenteropathy. History or current presence of peptic ulcers; current presence of Helicobacter pylori.
History of definitive acid-lowering surgery, previous esophageal surgery, or esophageal stricture is disallowed. History of fundoplication or feeding tube insertion is allowed.
Treatment with full therapeutic doses of H2-receptor antagonists or sucralfate within three days prior to dosing (or a shorter washout if agreed to by Investigator and Sponsor), except for cimetidine, which must be discontinued for at least seven days prior to dosing.
Treatment with a proton pump inhibitor within three days prior to dosing (or a shorter washout if agreed to by Investigator and Sponsor).
Inability to have 2-week PPI therapy-free period at end of active drug treatment.
Pregnancy or lactation.
Known or suspected drug addiction or alcohol abuse and/or a positive urine drug screen not explained by medication list; occasional alcohol or tobacco use is not an exclusion criterion.
Unwilling or unable to abide by the requirements of the study or violating the prohibitions and restrictions of the study defined in Section 9.4.
Any condition which would make the patient, in the opinion of the Investigator or Sponsor, unsuitable for the study.
Participation in another investigational drug study within one month prior to dosing.
A history of allergy/sensitivity to proton pump inhibitors or to their inactive ingredients.

Where it is running

Longmont Medical Research Network — Longmont, Colorado, United States
Nova Southeastern University — Fort Lauderdale, Florida, United States
Babies and Beyond Peds — New Port Richey, Florida, United States
Dr. Patricia Barrington, Dr. B. Abraham, PC — Snellville, Georgia, United States
Multi-specialty Clinical Research — Hoffman Estates, Illinois, United States
Kentucky Pediatric/Adult Research — Bardstown, Kentucky, United States
Professional Clinical Research — Cadillac, Michigan, United States
Community Pediatric Associates — Kalamazoo, Michigan, United States
The Center for Human Nutrition — Omaha, Nebraska, United States
Children's Hospital of Buffalo - Digestive Disease And Nutrition Center — Buffalo, New York, United States
Winthrop University Hospital — Mineola, New York, United States
Pediatric Associates of Mount Carmel, Inc. — Cincinnati, Ohio, United States
Pediatric Associates of Mt. Carmel — Cincinnati, Ohio, United States
University of Pediatrics — Mason, Ohio, United States
Center for Children's Digestive Health — Youngstown, Ohio, United States
Pharmacotherapy Research Associates — Zanesville, Ohio, United States
Biomedical Research Associates — Shippensburg, Pennsylvania, United States
DeGarmo Institute of Medicine Research — Greer, South Carolina, United States
Focus Research Group — Hendersonville, Tennessee, United States
ProMed Healthcare — Johnson City, Tennessee, United States
NE Ohio University College of Medicine — Lebanon, Tennessee, United States
Southwest Children's Research Associates — San Antonio, Texas, United States
Alpine Medical Group — Salt Lake City, Utah, United States
Rockwood Clinic North — Spokane, Washington, United States
Marshall University — Huntington, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.